Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

CervoMed (CRVO) Gains from Sales and Divestitures (2022 - 2023)

CervoMed (CRVO) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $1157.0 as the latest value for Q2 2023.